EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The therapeutic potential of RANTES/CCL5 across diverse infections and its synergistic enhancement by ezrin peptide RepG3 for long COVID

Rupert Holms

Microbes & Immunity · 2024

DOI: 10.36922/mi.2474 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbes & Immunity, 2024. Verfasst von Rupert Holms. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The amplification of anti-infective immunity against a wide spectrum of acute and chronic infections caused by various pathogens is mediated by RANTES/CCL5. This chemokine controls infections caused by viruses, bacteria, fungi, and protozoans. In addition, RANTES/CCL5 exhibits anti-cancer effects by increasing NK-cell activity and targeting tumors. RANTES/CCL5 acts by amplifying antigen-specific immunity on mucosal surfaces, programmed T-cell responses, cytotoxic T lymphocytes (CTL), B-cell activation, and antibody production. RANTES/CCL5 exerts its effects by binding to C-C receptors, thereby triggering JAK/STAT signaling and inducing the migration of lymphocytes, NK cells, and monocytes. In the brain, RANTES/CCL5 activates astrocytes and upregulates anti-inflammatory interleukin (IL)-10 expression. Inflammatory cytokines rapidly induce RANTES/CCL5 expression in fibroblasts, epithelial cells, and monocytes/macrophages. In T-cells, RANTES/CCL5 expression is mediated by translational control of the transcription factor RFLAT-1/KLF13, which is responsible for a 3-day delay in RANTES/CCL5 secretion after T-cell activation. A cell membrane multi-protein complex containing CFTR, EBP50, ezrin, and PKC is a dominant regulator of both RANTES/CCL5 and inflammatory cytokine expression. Treatment of a volunteer patient suffering from long COVID/vaccine injury with the ezrin peptide RepG3 alleviated symptoms, substantially reduced serum proinflammatory cytokines to normal levels, and enhanced the expression of RANTES/CCL5. The immune amplification activities of RANTES/CCL5 and the ezrin peptide RepG3 exhibit striking similarities. In contrast, the ezrin peptide RepG3 differs from RANTES/CCL5 in its ability to significantly inhibit the expression of proinflammatory cytokines IL-1β, IL-6, IL-8, IL-13, TNF-α, and proinflammatory chemokines MIP-1α and MIP-1β. The mechanism through which the ezrin peptide RepG3 enhances adaptive immunity likely involves its induction of systemic elevation of RANTES/CCL5 expression and the simultaneous inhibition of proinflammatory cytokine expression.

Zitieren

APA

Holms, R. (2024). The therapeutic potential of RANTES/CCL5 across diverse infections and its synergistic enhancement by ezrin peptide RepG3 for long COVID. Microbes & Immunity. https://doi.org/10.36922/mi.2474

Vancouver

Holms R. The therapeutic potential of RANTES/CCL5 across diverse infections and its synergistic enhancement by ezrin peptide RepG3 for long COVID. Microbes & Immunity. 2024. doi:10.36922/mi.2474

BibTeX
@article{Holms2024,
  author = {Holms, Rupert},
  title = {The therapeutic potential of RANTES/CCL5 across diverse infections and its synergistic enhancement by ezrin peptide RepG3 for long COVID},
  journal = {Microbes & Immunity},
  year = {2024},
  doi = {10.36922/mi.2474}
}
Kostenlos starten →